Moreover, a 4-day FICZ treatment was sufficient to significantly reduce the clonogenic potential of CML CD34+ cells and this effect was synergized by Imatinib and Dasatinib treatments. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.